Plus   Neg

Prologis Cuts 2020 Profit Outlook

Prologis Inc. (PLD) said that it cuts its profit outlook for fiscal year 2020.

"While the full economic impact of the pandemic is difficult to quantify, we have analyzed numerous scenarios and have adjusted our guidance to account for a broad range of outcomes," said Thomas Olinger, chief financial officer, Prologis.

The company has have assumed reduced demand into the third quarter and anticipates that the operating environment will begin to recover toward the end of the year.

The company cut its annual net earnings per share outlook to a range of $1.81 to $1.88 from the prior estimation of $1.98 to $2.13 per share. Analysts polled by Thomson Reuters expect the company to report earnings of $1.57 per share for fiscal year 2020. Analysts' estimates typically exclude special items.

The company now projects annual Core FFO to be in the range of $3.55 to $3.65, compared to the prior estimation of $3.67 to $3.75.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Shares of Volkswagen Group were gaining around 3 percent in German trading after the automotive giant Thursday reported market recovery in the third quarter with improved deliveries in the month of September. For the first nine months of fiscal 2020, the company, meanwhile reported sharply lower earnings with weak revenues and sales volume. Comcast Corp. on Thursday reported a 37 percent decline in profit for the third quarter from last year, hurt primarily by revenue decline at NBCUniversal. Both adjusted earnings per share and quarterly revenues topped analysts' expectations. The company also declared a quarterly dividend. In the pre-market trade, CMCSA is trading at $42.83, up $0.85 or 2.02 percent. Regeneron announced positive results from its late stage COVID-19 outpatient trial, indicating that its antibody cocktail therapy significantly reduced virus levels and need for further medical attention. The trial results showed that investigational antibody cocktail, REGN-COV2, met the primary and key secondary endpoints.
Follow RTT